Cardiomyocyte-specific deletion of leptin receptors causes lethal heart failure in Cre-recombinase-mediated cardiotoxicity

Michael E. Hall1,2, Grant Smith1, John E. Hall1, David E. Stec1
1Department of Physiology and Biophysics, 1Center for Excellence in Cardiovascular-Renal Research, Department of Medicine,
2Division of Cardiology, University of Mississippi Medical Center, Jackson, Mississippi

Tóm tắt

Although disruption of leptin signaling is associated with obesity as well as cardiac lipid accumulation and dysfunction, it has been difficult to separate the direct effects of leptin on the heart from those associated with the effects of leptin on body weight and fat mass. Using Cre-loxP recombinase technology, we developed tamoxifen-inducible, cardiomyocyte-specific leptin receptor-deficient mice to assess the role of leptin in regulating cardiac function. Cre recombinase activation in the heart resulted in transient reduction in left ventricular systolic function which recovered to normal levels by day 10. However, when cardiomyocyte leptin receptors were deleted in the setting of Cre recombinase-induced left ventricular dysfunction, irreversible lethal heart failure was observed in less than 10 days in all mice. Heart failure after leptin receptor deletion was associated with marked decreases of cardiac mitochondrial ATP, phosphorylated mammalian target of rapamycin (mTOR), and AMP-activated kinase (pAMPK). Our results demonstrate that specific deletion of cardiomyocyte leptin receptors, in the presence of increased Cre recombinase expression, causes lethal heart failure associated with decreased cardiac energy production. These observations indicate that leptin plays an important role in regulating cardiac function in the setting of cardiac stress caused by Cre-recombinase expression, likely through actions on cardiomyocyte energy metabolism.

Từ khóa


Tài liệu tham khảo

10.1074/jbc.C300557200

10.1074/jbc.M203813200

10.1161/01.RES.0000199348.10580.1d

10.1016/j.cardfail.2006.03.002

10.1152/physiolgenomics.2001.5.2.89

10.1002/9780470985571.ch7

10.1172/JCI200113914

10.1161/CIRCULATIONAHA.108.769984

10.1038/nature06322

10.1126/science.1063518

10.1161/01.HYP.0000198555.51645.f1

10.1677/joe.1.06241

10.1152/ajpregu.00264.2003

10.1097/01.hjh.0000239304.01496.83

10.1152/japplphysiol.01313.2006

10.1055/s-2003-39786

10.1152/ajpheart.00786.2010

10.1101/gad.1212704

10.1073/pnas.2134694100

10.1038/38717

10.1161/CIRCRESAHA.109.198416

10.1161/CIRCULATIONAHA.107.728865

10.1016/j.echo.2005.10.005

10.1161/01.RES.0000181132.11393.18

10.1073/pnas.161269798

10.1161/CIRCRESAHA.107.150417

10.1074/jbc.M706706200

10.1093/cvr/cvm023

10.1093/cvr/cvq288

10.1093/cvr/cvp071

10.1161/01.CIR.0000130641.08705.45

10.1042/bst0310196

10.1038/415339a

10.1161/01.HYP.0000144292.69599.0c

10.1152/ajpendo.00111.2006

10.2165/00002018-200022040-00002

10.1016/j.metabol.2006.03.020

Parlakian A, 2005, Circulation, 112, 2930, 10.1161/CIRCULATIONAHA.105.533778

10.1210/jc.2004-1963

10.1016/j.cardfail.2011.08.010

10.1016/j.cardiores.2007.05.004

10.2337/db10-1106

10.1161/hh1301.092687

10.2337/db09-0638

10.1016/j.metabol.2005.04.007

10.1161/01.HYP.0000165683.09053.02

10.1016/j.yjmcc.2012.03.016

10.1161/CIRCULATIONAHA.106.631093